| Species |
Human |
| Protein Construction |
Periostin/OSF-2 (Asn22-Gln836)_x000D_
Accession # Q15063 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Periostin/OSF-2, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiPeriostin Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
92.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 93-100 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Periostin is a matricellular protein that is expressed in several tissues during embryonic development; however, its expression in adults is mostly restricted to collagen-rich connective tissues. Periostin is expressed only briefly during kidney development, but it is not normally detected in the adult kidney. Recent evidence has revealed that periostin is aberrantly expressed in several forms of chronic kidney disease (CKD), and that its expression correlates with the degree of interstitial fibrosis and the decline in renal function. |
| Synonyms |
Periostin; PN; OSF-2; POSTN; OSF2; Fasciclin I-like; PDLPOSTN; PNRP11-412K4.1; TRIF52 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
